|
Baseline clinical data |
|||||
| Variable Mean ± SD (Range) |
Insulin (n = 8) |
Sulfonylurea (n = 5) |
Metformin (n = 6) |
Thiazoli-dinediones (n = 6) |
P Value |
|
|
|||||
| Age (Yrs) |
26.0 ± 10.3 (13 – 44) |
24.4 ± 6.9 (17 – 33) |
22.8 ± 6.7 (15 – 35) |
34.0 ± 9.9 (20 – 49) |
0.166 |
| ALT (U/L) |
65.1 ± 24.1 (25 – 99) |
42.0 ± 26.5 (14 – 73) |
68.3 ± 28.1 (28 – 107 |
67.4 ± 8.4 (55 – 76) (n = 5) |
0.250 |
| FEV1 (%) |
56.8 ± 28.0 (18 – 99) |
53.0 ± 23.3 (30 – 83) |
79.2 ± 34.5 (17 – 117) |
52.0 ± 25.2 (3 – 92) |
0.329 |
| Weight (kg) |
60.2 ± 12.9 (41.9 – 81.5) |
66.0 ± 24.8 (33.6 – 97.5) |
61.8 ± 12.2 (41.8 – 71.1) |
65.7 ± 20.4 (44.4 – 96.5) |
0.911 |
| HbA1c |
9.5 ± 2.6 (5.5 – 14.3) |
7.2 ± 0.8 (6.3 – 8.1) |
8.8 ± 2.8 (5.4 – 13.3) |
8.0 ± 3.1 (5.1 – 13.3) |
0.408 |
| Treatment Duration (Yrs) |
4.8 ± 2.9 (2 – 10) |
1.8 ± 1.3 (1 – 4) |
2.7 ± 1.4 (1 – 5) |
1.8 ± 0.4 (1 – 2) |
0.093 |
|
SD, standard deviation; Yrs, years; ALT, alanine aminotransferase; FEV1, forced expiratory volume at 1 second; HbA1c, percent glycosylated hemoglobin. P values for Age, ALT, FEV1, Weight, and HbA1c are from one-way analysis of variance (ANOVA); the P value for Treatment Duration is from Welch ANOVA for unequal group variances. | |||||
Onady and Langdon BMC Endocrine Disorders 2006 6:4 doi:10.1186/1472-6823-6-4 |
|||||